SEC Form 4 · accession 0001864158-26-000006
Janux Therapeutics, Inc. · JANX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Alan Campbell
Officer — President and CEO · Director
Period of report
Jul 31, 2026
Accepted (ET)
Jul 31, 2026 · 8:00 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001817713
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 31, 2026 | G | 123,840 | $0.00 | D | 264,742 | D |
Table II — derivative securities
No Table II lines on this filing.